Celldex Therapeutics Dosed the First Patient with CDX-0159 for Prurigo Nodularis
Celldex Therapeutics (CLDX) announced that the first patient in a Phase 1 study of CDX-0159 for prurigo nodularis (PN) has been already dosed.
From Celldex Therapeutics
Diane C. Young, MD, Senior Vice President and Chief Medical Officer of . . .
This content is for paid subscribers.
Today’s Highlights December 8, 2021